{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"17"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"51"}],"units":"Participants"}],"title":"Attempted PBSC Collection"},{"categories":[{"measurements":[{"groupId":"OG000","value":"17"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"17"}],"units":"Participants"}],"title":"Successful PBSC Collection"}],"denoms":[{"counts":[{"groupId":"OG000","value":"51"}],"units":"Participants"}],"description":"Count of patients that attempted and had successful autologous peripheral blood stem cell (PBSC) collection.","groups":[{"description":"Patients receive gemcitabine hydrochloride intravenously (IV) over 30 minutes on days 1 and 8, carboplatin IV over 30-60 minutes on day 1, and dexamethasone orally (PO) on days 1-4. Treatment repeats every 21 days for up to 4 courses in the absence of disease progression or unacceptable toxicity. Patients with CD20-POSITIVE LYMPHOMAS also receive rituximab IV on day 8.","id":"OG000","title":"Treatment"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"Successful PBSC collection is only considered in those patients that attempted PBSC collection.","reportingStatus":"POSTED","timeFrame":"Up to 12 weeks","title":"Peripheral Blood Stem Cell Collection","type":"SECONDARY","unitOfMeasure":"Participants"}